LAIS Grass / Lofarma - LARVOL DELTA

Efficacy and safety of sublingual immunotherapy with LAIS grass tablets allergoid for patients with grass pollen-induced allergic moderate/severe rhinoconjunctivitis (EAACI 2022) - "Background: Allergoids are modified allergens with an altered protein structure which are aimed at reducing allergenicity while maintaining immunogenicity and thus efficacy of allergen immunotherapy. No treatment-related SAEs were reported in any patient and no use of epinephrine was necessary. Conclusion This trial indicates Grass allergoid tablet is associated to a clinically relevant significant improvement in AR symptoms and use of antiallergic medications, consistent during the grass peak and season, with low incidence of mild adverse reactions."

Clinical • Immunology